Provided by Tiger Trade Technology Pte. Ltd.

Sagimet Biosciences Inc.

10.99
+0.49004.67%
Post-market: 11.250.2593+2.36%19:57 EDT
Volume:1.80M
Turnover:19.56M
Market Cap:683.12M
PE:-8.80
High:11.06
Open:10.51
Low:10.51
Close:10.50
52wk High:11.15
52wk Low:4.50
Shares:62.16M
Float Shares:55.78M
Volume Ratio:2.30
T/O Rate:3.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2490
EPS(LYR):-1.5800
ROE:-24.37%
ROA:-16.41%
PB:2.67
PE(LYR):-6.96

Loading ...

Sagimet Biosciences to Present at Cantor Global Healthcare Conference

Reuters
·
Yesterday

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

GlobeNewswire
·
Yesterday

Sagimet Biosciences Price Target Maintained with a $29.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 25

Sagimet Reiterated as Buy on De-Risked Acne Program and Clearer Regulatory Path; $29 Price Target Maintained

TIPRANKS
·
Aug 25

Sagimet Biosciences advances AURORA clinical trial

TIPRANKS
·
Aug 25

Sagimet Advances Aurora Phase 3 Acne Trial of Denifanstat, Targets Q4 2026 Enrollment

Reuters
·
Aug 25

Sagimet Biosciences Advances Aurora U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

THOMSON REUTERS
·
Aug 25

Sagimet Biosciences - Patient Screening for Aurora Phase 3 Trial to Begin in October 2026

THOMSON REUTERS
·
Aug 25

Sagimet Biosciences Inc.: Anticipate Submitting an Nda upon Completion of 12-Week Phase of Study

THOMSON REUTERS
·
Aug 25

Sagimet Biosciences - All Clinical Trial Sites Identified and Cro Retained for Aurora Phase 3 Trial

THOMSON REUTERS
·
Aug 25

Sagimet Biosciences Grants 260,700 Inducement Stock Options to New Hires

Reuters
·
Aug 18

Sagimet Biosciences Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 18

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 18

Sagimet Biosciences price target raised to $56 from $49 at Canaccord

TIPRANKS
·
Aug 17

Sagimet Wins FDA IND Clearance for Phase 3 Denifanstat Acne Trial

Reuters
·
Aug 13

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and Ind Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

THOMSON REUTERS
·
Aug 13

Sagimet Biosciences Inc.: Phase 3 Clinical Trial is on Track to Initiate in Second Half of 2026

THOMSON REUTERS
·
Aug 13

Sagimet Director George Kemble Disposes of 20,206 Common Shares Worth $201,160.97

Reuters
·
Aug 13

Sagimet Biosciences Price Target Raised to $56.00/Share from $49.00 by Canaccord Genuity

Dow Jones
·
Aug 13

Edward Nash Initiates Buy on Sagimet, Citing De-Risked Late-Stage Acne Program and Significant U.S. Market Opportunity

TIPRANKS
·
Aug 12